Showing 141 - 160 results of 1,041 for search '"mutant"', query time: 0.05s Refine Results
  1. 141

    <i>Staphylococcus aureus</i> Proteins Implicated in the Reduced Virulence of <i>sarA</i> and <i>sarA/agr</i> Mutants in Osteomyelitis by Karen E. Beenken, Mara J. Campbell, Stephanie D. Byrum, Rick D. Edmondson, Samuel G. Mackintosh, Alan J. Tackett, Mark S. Smeltzer

    Published 2025-01-01
    “…Using a murine osteomyelitis model, we recently demonstrated that <i>Staphylococcus aureus sarA</i> and <i>sarA/agr</i> mutants generated in the USA300 strain LAC are attenuated to a greater extent than an isogenic <i>agr</i> mutant and that this can be attributed to a significant extent to the increased production of extracellular proteases in both mutants. …”
    Get full text
    Article
  2. 142

    EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells by Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, Azam Safary, Khosro Adibkia

    Published 2025-01-01
    “…This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), an anti-EGFR monoclonal antibody, through a polyethylene glycol (PEG) linker (RN-PEG-Cet), aimed to induce apoptosis in KRAS mutant colorectal cancer (CRC) via a ROS-mediated pathway. …”
    Get full text
    Article
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148

    Molecular dynamics simulation of wild and mutant proteasome subunit beta type 8 (PSMB8) protein: Implications for restoration of inflammation in experimental autoimmune encephalomyelitis pathogenesis by Shamrat Kumar Paul, Md Saddam, Nisat Tabassum, Mahbub Hasan

    Published 2025-01-01
    “…Therefore, special attention to wild and mutant (G210V) PSMB8 protein is imperative. In this study, we performed a 100 ns molecular dynamics (MD) simulation for wild-type PSMB8 and the mutant G210V. …”
    Get full text
    Article
  9. 149

    CYTOTYPES OF MUTANT DROSOPHILA MELANOGASTER STOCKS FROM THE COLLECTION OF THE GENETICS OF POPULATION LABORATORY OF THE INSTITUTE OF CYTOLOGY AND GENETICS SB RAS: GENOTYPES OF THE WOLBACHIA ENDOSYMBIONT AND HOST MITOTYPES by Yu. Yu. Ilinsky, R. A. Bykov, I. K. Zakharov

    Published 2015-01-01
    “…However, there are no sufficient data on Wolbachia infection among laboratory mutant stocks. We show the wide prevalence of Wolbachia among 353 mutant stocks from the collection of the Genetics of Populations Laboratory, Institute of Cytology and Genetics (ICG), Novosibirsk, Russia. …”
    Get full text
    Article
  10. 150

    Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

    Published 2025-01-01
    “…Conclusion This modified combination regimen may be a promising therapeutic option for EGFR‐mutant NSCLC patients with TKI resistance, especially those with PD‐L1‐positive tumours. …”
    Get full text
    Article
  11. 151
  12. 152

    Karyopherin Alpha 2-Expressing Pancreatic Duct Glands and Intra-Islet Ducts in Aged Diabetic C414A-Mutant-CRY1 Transgenic Mice by Satoshi Okano, Akira Yasui, Shin-ichiro Kanno, Kennichi Satoh, Masahiko Igarashi, Osamu Nakajima

    Published 2019-01-01
    “…Our earlier studies demonstrated that cysteine414- (zinc-binding site of mCRY1-) alanine mutant mCRY1 transgenic mice (Tg mice) exhibit diabetes characterized by the reduction of β-cell proliferation and by β-cell dysfunction, presumably caused by senescence-associated secretory phenotype- (SASP-) like characters of islets. …”
    Get full text
    Article
  13. 153

    HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer by Xin Li, Peng Yang, Jin Gu, Nan Chen, Dengbo Ji, Jinhong Xia, Jinying Jia, Zhuang Sun, Mengyuan Shi, Hanyang Wang, Zhaoya Gao

    Published 2025-01-01
    “…Background B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E-mutant microsatellite stable (MSS) colorectal cancer (CRC) constitutes a distinct CRC subgroup, traditionally perceived as minimally responsive to standard therapies. …”
    Get full text
    Article
  14. 154
  15. 155
  16. 156

    Effects of EGFR-TKIs combined with intracranial radiotherapy in EGFR-mutant non-small cell lung cancer patients with brain metastases: a retrospective multi-institutional analysis by Mingfeng He, Xue Wu, Li Li, Guangming Yi, Yitian Wang, Hengqiu He, Ying Ye, Ruiqin Zhou, Zaicheng Xu, Zhenzhou Yang

    Published 2025-01-01
    “…In clinical practice, treatment-naïve EGFR-mutant NSCLC patients with asymptomatic BMs tend to choose EGFR-tyrosine kinase inhibitors (TKIs) as first-line therapy and defer intracranial radiotherapy (RT). …”
    Get full text
    Article
  17. 157

    A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer by Sara Roth, Kasmira Claire Wilson, Robert George Ramsay, Catherine Mitchell, Shienny Sampurno, Toan Duc Pham, Joseph Cherng Huei Kong, Stephen Q. Wong, Alexander Graham Heriot, Sanjeev Deva, Matthew Burge, Cecilie Sverdrup, Anne-Sophie Moller, Lukasz Kuryk, Jon Amund Eriksen, Magnus Jaderberg, John Raymond Zalcberg, Michael Michael

    Published 2025-01-01
    “…This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with KRAS-mutant colorectal cancer. Methods: In the interval between completing CRT and pelvic exenteration, patients with resectable KRAS mutation-positive, locally advanced primary or current colorectal cancer, received 5–6 doses of TG02/GM-CSF. …”
    Get full text
    Article
  18. 158

    Host–virus interactions during infection with a wild-type ILTV strain or a glycoprotein G deletion mutant ILTV vaccine strain in an ex vivo system by Gayathri Gopakumar, Mauricio J.C. Coppo, Andrés Diaz-Méndez, Carol A. Hartley, Joanne M. Devlin

    Published 2025-02-01
    “…ABSTRACT Previous studies have demonstrated the safety and efficacy of a live-attenuated glycoprotein G (gG) deletion mutant vaccine strain of ILTV (∆gG-ILTV). In the current study, transcriptional profiles of chicken tracheal organ cultures (TOCs), 24 h post inoculation with ∆gG-ILTV or the gG-expressing parent wild-type strain, CSW-1 ILTV were explored and compared with the mock-infected TOCs using RNA-seq analysis. …”
    Get full text
    Article
  19. 159
  20. 160